Trial Information

Summary: Phase I Multi-center Study of Intravenous BCX-1777 in Patients with Refractory Hematologic Malignancies

BCX-1777 is a new medication that is effective at killing cancer cells in the laboratory. This study is being done to determine the correct dose to be given to patients.
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

1. Any hematologic malignancy that has recurred after previous therapy
2. Normal liver and kidney function
3. Age over 18 years

1. Candidates for stem-cell transplantation
2. Concurrent treatment with an anti-cancer agent

Contact:

Richard Furman, M.D.
Mount Sinai Medical Center
One Gustave L. Levy Place

New York, NY 10029
Telephone: 212 241-5454
Fax: 212 876-5276
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:32 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA